当前位置：
X-MOL 学术
›
ACS Med. Chem. Lett.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology Agent.
ACS Medicinal Chemistry Letters ( IF 3.5 ) Pub Date : 2020-01-28 , DOI: 10.1021/acsmedchemlett.9b00552 Upender Velaparthi 1 , Chetan Padmakar Darne 1 , Jayakumar Warrier 2 , Peiying Liu 1 , Hasibur Rahaman 2 , Karen Augustine-Rauch 1 , Karen Parrish 1 , Zheng Yang 1 , Jesse Swanson 1 , Jennifer Brown 1 , Gopal Dhar 2 , Aravind Anandam 2 , Vinay K Holenarsipur 2 , Kamalavenkatesh Palanisamy 2 , Barri S Wautlet 1 , Mark P Fereshteh 1 , Jonathan Lippy 1 , Andrew J Tebben 1 , Steven Sheriff 1 , Max Ruzanov 1 , Chunhong Yan 1 , Anuradha Gupta 2 , Arun Kumar Gupta 2 , Muthalagu Vetrichelvan 2 , Arvind Mathur 1 , Marina Gelman 3 , Rajinder Singh 3 , Todd Kinsella 3 , Anwar Murtaza 1 , Joseph Fargnoli 1 , Gregory Vite 1 , Robert M Borzilleri 1
ACS Medicinal Chemistry Letters ( IF 3.5 ) Pub Date : 2020-01-28 , DOI: 10.1021/acsmedchemlett.9b00552 Upender Velaparthi 1 , Chetan Padmakar Darne 1 , Jayakumar Warrier 2 , Peiying Liu 1 , Hasibur Rahaman 2 , Karen Augustine-Rauch 1 , Karen Parrish 1 , Zheng Yang 1 , Jesse Swanson 1 , Jennifer Brown 1 , Gopal Dhar 2 , Aravind Anandam 2 , Vinay K Holenarsipur 2 , Kamalavenkatesh Palanisamy 2 , Barri S Wautlet 1 , Mark P Fereshteh 1 , Jonathan Lippy 1 , Andrew J Tebben 1 , Steven Sheriff 1 , Max Ruzanov 1 , Chunhong Yan 1 , Anuradha Gupta 2 , Arun Kumar Gupta 2 , Muthalagu Vetrichelvan 2 , Arvind Mathur 1 , Marina Gelman 3 , Rajinder Singh 3 , Todd Kinsella 3 , Anwar Murtaza 1 , Joseph Fargnoli 1 , Gregory Vite 1 , Robert M Borzilleri 1
Affiliation
|
Novel imidazole-based TGFβR1 inhibitors were identified and optimized for potency, selectivity, and pharmacokinetic and physicochemical characteristics. Herein, we report the discovery, optimization, and evaluation of a potent, selective, and orally bioavailable TGFβR1 inhibitor, 10 (BMS-986260). This compound demonstrated functional activity in multiple TGFβ-dependent cellular assays, excellent kinome selectivity, favorable pharmacokinetic properties, and curative in vivo efficacy in combination with anti-PD-1 antibody in murine colorectal cancer (CRC) models. Since daily dosing of TGFβR1 inhibitors is known to cause class-based cardiovascular (CV) toxicities in preclinical species, a dosing holiday schedule in the anti-PD-1 combination efficacy studies was explored. An intermittent dosing regimen of 3 days on and 4 days off allowed mitigation of CV toxicities in one month dog and rat toxicology studies and also provided similar efficacy as once daily dosing.
中文翻译：
发现了BMS-986260，这是一种有效，选择性和口服生物利用的TGFβR1抑制剂，可作为免疫肿瘤药。
鉴定了基于咪唑的新型TGFβR1抑制剂，并对其效价，选择性以及药代动力学和理化特性进行了优化。本文中，我们报告了一种有效的，选择性的和口服生物利用的TGFβR1抑制剂10（BMS-986260）的发现，优化和评估。在鼠大肠癌（CRC）模型中，该化合物在多种TGFβ依赖性细胞试验中具有功能活性，优异的激酶组选择性，良好的药代动力学特性以及与抗PD-1抗体结合的治愈性体内疗效。由于已知每天服用TGFβR1抑制剂会在临床前物种中引起基于类别的心血管（CV）毒性，因此在抗PD-1联合功效研究中探索了给药假期时间表。
更新日期：2020-02-04
中文翻译：
发现了BMS-986260，这是一种有效，选择性和口服生物利用的TGFβR1抑制剂，可作为免疫肿瘤药。
鉴定了基于咪唑的新型TGFβR1抑制剂，并对其效价，选择性以及药代动力学和理化特性进行了优化。本文中，我们报告了一种有效的，选择性的和口服生物利用的TGFβR1抑制剂10（BMS-986260）的发现，优化和评估。在鼠大肠癌（CRC）模型中，该化合物在多种TGFβ依赖性细胞试验中具有功能活性，优异的激酶组选择性，良好的药代动力学特性以及与抗PD-1抗体结合的治愈性体内疗效。由于已知每天服用TGFβR1抑制剂会在临床前物种中引起基于类别的心血管（CV）毒性，因此在抗PD-1联合功效研究中探索了给药假期时间表。
京公网安备 11010802027423号